Ocuphire Pharma Announces Presentation On APX3330 At The Annual Angiogenesis, Exudation, And Degeneration 2024 Conference
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma, Inc. (NASDAQ:OCUP) presented clinical data from its ZETA-1 trial on APX3330 for diabetic retinopathy at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference. The trial showed a reduction in disease worsening with 24 weeks of APX3330 treatment. Ocuphire plans to finalize the Phase 3 program protocol with the FDA, highlighting APX3330's potential as an oral treatment option for non-proliferative diabetic retinopathy.
February 05, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocuphire Pharma presented positive clinical data from its ZETA-1 trial on APX3330 for diabetic retinopathy, planning to finalize Phase 3 protocol with the FDA.
The presentation of positive clinical data from the ZETA-1 trial and the plans to finalize the Phase 3 protocol with the FDA are significant developments for Ocuphire Pharma. These steps indicate progress in the development of APX3330 as a potential treatment for diabetic retinopathy, which could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100